Latest news with #GenflowBiosciencesPlc
Associated Press
5 days ago
- Business
- Associated Press
Genflow Confirms Progression of Grant
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Genflow Confirms Approximately €4M Grant Support from Wallonia Region; GF-1002 Program Progressing without Interruption LONDON, UK / ACCESS Newswire / July 17, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ('Genflow' or 'the Company'), the only publicly listed longevity company in Europe, is pleased to reaffirm the previously announced award of approximately €4 million in non-dilutive financial support from the Wallonia Region of Belgium, supporting the development of its lead gene therapy candidate, GF-1002, for the treatment of Metabolic Associated Steatohepatitis (MASH). Read the RNS announcing this grant here. The support package spans a three-year development program, aligned with Genflow's existing clinical roadmap. All project-related expenses incurred in 2025 will be considered eligible. While initial disbursement is pending the completion of standard administrative procedures on the government's side, Genflow has taken proactive steps to ensure the continuity of its GF-1002 program and confirms that progress remains on track with no delays to planned research or development activities. Dr. Eric Leire, CEO of Genflow, commented: 'We greatly appreciate the continued support from the Wallonia Region. The €4 million in non-dilutive funding represents a significant endorsement of our science and our strategy. We remain fully focused on advancing GF-1002 through the next stage of development and have ensured that operations proceed uninterrupted as the program moves forward.' Contacts About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and X. DISCLAIMER The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words 'anticipate', 'believe', 'continue', 'could', 'estimate', 'expect', 'intend', 'may', 'might', 'plan', 'possible', 'potential', 'predict', 'project', 'seek', 'should', 'would' and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions. Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Genflow Biosciences PLC press release
Yahoo
22-05-2025
- Business
- Yahoo
Genflow Biosciences PLC Announces AGM Notice
LONDON, UNITED KINGDOM / / May 22, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 9am on Thursday 12 June 2025 at One Heddon Street, London, W1B 4BD. The Notice of the AGM ("Notice") and 2025 Form of Proxy will shortly be available on the Company's website, and was, where applicable, posted to shareholders on 19 May 2025. Further details of the arrangements for this year's AGM are set out in the Notice. As announced on 30 April 2025, the Company's Annual Report and Accounts for the year ended 31 December 2024 are also available on the website and has, where applicable, also been posted to registered shareholders. Contacts Genflow Biosciences Harbor Access Dr Eric Leire, CEO Jonathan Paterson, Investor Relations +32-477-495-881 +1 475 477 9401 Brokers Capital Plus Partners Ltd Dominic Berger, +44 203 821 6167 Jon Critchley, +44 0203 821 6168 About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and Twitter/X. -Ends- This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Genflow Biosciences PLC View the original press release on ACCESS Newswire Sign in to access your portfolio
